Ipamorelin vs CJC-1295 with DAC
Side-by-Side Comparison
| Attribute | Ipamorelin | Cjc 1295 Dac |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating... | CJC-1295 DAC binds to GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase via Gs coupling and increasing cAMP. This stimulates GH synthesis and release. |
| Evidence Rating | D — Preclinical | C — Phase I-II data; research compound |
| Clinical Status | Research-only / Not approved for human use | Research compound. Phase 1/2 clinical data exists (ConjuChem). Not approved for any indication. |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | Water retention and edema reported, particularly facial puffiness; Numbness and tingling in extremities |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | 100–300 mcg per injection, 2–3x daily | 1-2 mg per injection |
| Frequency | 2–3 times daily (typically before meals and before bed) | 1-2x per week |
| Molecular Weight | ~711.9 g/mol | ~3647 g/mol (peptide) + DAC linker |
| Half-Life | ~2 hours | ~8 days |
Overview
Ipamorelin and CJC-1295 with DAC are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
CJC-1295 with DAC — Mechanism & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a modified growth hormone-releasing hormone (GHRH) analog with a unique lysine-linked maleimidopropionic acid moiety that covalently binds to circulating albumin in vivo. This albumin binding extends the half-life from minutes (native GHRH) to approximately 8 days, allowing once- or twice-weekly dosing while maintaining sustained GH elevation. Unlike CJC-1295 without DAC (which preserves pulsatile GH release), the DAC version produces a continuous GH elevation pattern. This is both its advantage (convenience) and disadvantage (non-physiological GH pattern).
Key claims: Sustained growth hormone elevation; Convenient weekly dosing schedule; Improved body composition.
Shared Research Applications
Both peptides are studied for: Body Composition.
Ipamorelin is also researched for: Anti-Aging, Sleep.
CJC-1295 with DAC is also researched for: Growth Hormone, Recovery.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
CJC-1295 with DAC: Water retention and edema reported, particularly facial puffiness Numbness and tingling in extremities Joint pain consistent with GH elevation
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
Ipamorelin vs GHRP-2: Which Offers More Targeted GH Release?
Ipamorelin and GHRP-2 both stimulate growth hormone release via the ghrelin receptor, but Ipamorelin provides more selective action with minimal impact on other hormones like ACTH and cortisol. GHRP-2 delivers stronger GH pulses alongside broader endocrine effects. Combining them can enhance overall GH output through additive receptor stimulation.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.